09:42 AM EDT, 07/11/2025 (MT Newswires) -- CEL-SCI ( CVM ) said Friday it has reached an agreement with a Saudi Arabian pharmaceutical company for a partnership covering regulatory and commercial projects in the country for Multikine to treat head and neck cancer.

The formal agreement is expected to be signed with the Saudi company, which will submit a breakthrough medicine designation application for Multikine to the country's Food and Drug Authority in coming weeks, CEL-SCI ( CVM ) said.

According to the regulator, the response time to a breakthrough medicine designation application is about 60 days, the company said, adding that Multikine would be immediately available in Saudi Arabia after the granting of the designation.

The company also said several Saudi funds have indicated interest in investing in Multikine, CEL-SCI ( CVM ), and/or a potential joint venture for the Middle East and North Africa market.

Financial details weren't provided.

CEL-SCI ( CVM ) shares surged more than 57% in Friday early trading.

Price: 5.96, Change: +2.18, Percent Change: +57.67